Agile Therapeutics, Inc. (OTCQB:AGRX) Q1 2020 Earnings Conference Call May 5, 2020 4:30 PM ET Company Participants Matthew Riley - IR Alfred Altomari - Chairman, President & CEO Dennis Reilly - SVP & CFO Conference Call Participants Daniel Busby - RBC Capital Markets Timothy Lugo - William Blair & Company Leland Gershell - Oppenheimer Oren Livnat - H.C. Wainwright & Co. Esther Hong - Janney Montgomery Scott Operator Greetings, and welcome to the Agile Therapeutics First Quarter 2020 Financial Results Confer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other ...

Use these links to rapidly review the document Table of Contents Item 8. Financial Statements and Supplementary Data Title of each class Trading Symbol(s) Name of exchange on which registered: Common stock, par value $0.0001 per share AGRX The Nasdaq Capital Market Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 OR o TRANSITION REPORT ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or o ...

Twirla's Market Opportunity and Strategy - Agile's corporate strategy is to become a leader in women's health, starting with Twirla in the prescription contraceptive market [10] - The U S contraceptive market is a significant opportunity, estimated at $5 56 billion in 2017, with combined hormonal contraception (CHC) accounting for $3 8 billion [24, 25, 30] - Twirla has the potential for significant market share, with peak TRx share estimates based on market research and analogs suggesting 14% to 23% [31] Twirla's Clinical Trial Data and Regulatory Status - The SECURE trial, a Phase 3 study with approximately 2000 subjects, showed a low rate of hormone-related adverse events and a bleeding profile similar to low-dose oral CHCs [36, 37, 69, 72] - The overall serious adverse events (SAEs) were observed in 1 97% of the SECURE trial study population [70] - A life table analysis showed a failure rate of 4 2% at Cycle 13, inclusive of all subjects regardless of BMI [64] - A comparative wear study demonstrated non-inferior adhesion of Twirla to Xulane, with Twirla having a mean adhesion score of 0 14 compared to Xulane's 0 39 [85, 86, 87] Agile's Commercialization Plan - Agile is reactivating its plan for commercialization of Twirla, focusing on manufacturing, market access, launch network, and a targeted sales force of 70-100 representatives [47, 48] - The company completed a comparative wear study in February 2019 and resubmitted the Twirla NDA to the FDA in June 2019 [40, 57] - Agile expects to launch into a $3 8 billion addressable market [57]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other ...

Use these links to rapidly review the document Table of Contents Item 8. Financial Statements and Supplementary Data Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Ther ...